Quest Diagnostics Incorporated (LON:0KSX)
180.60
-0.52 (-0.29%)
At close: Sep 16, 2025
Quest Diagnostics Revenue
Quest Diagnostics had revenue of $2.76B USD in the quarter ending June 30, 2025, with 15.19% growth. This brings the company's revenue in the last twelve months to $10.52B, up 12.58% year-over-year. In the year 2024, Quest Diagnostics had annual revenue of $9.87B with 6.70% growth.
Revenue (ttm)
$10.52B
Revenue Growth
+12.58%
P/S Ratio
1.92
Revenue / Employee
$187.89K
Employees
56,000
Market Cap
14.76B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.87B | 620.00M | 6.70% |
Dec 31, 2023 | 9.25B | -631.00M | -6.38% |
Dec 31, 2022 | 9.88B | -905.00M | -8.39% |
Dec 31, 2021 | 10.79B | 1.35B | 14.32% |
Dec 31, 2020 | 9.44B | 1.71B | 22.15% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Quest Diagnostics News
- 15 days ago - Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index - PRNewsWire
- 22 days ago - Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan - PRNewsWire
- 23 days ago - FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics - PRNewsWire
- 4 weeks ago - Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference - PRNewsWire
- 4 weeks ago - Quest Diagnostics declares $0.80 dividend - Seeking Alpha
- 5 weeks ago - Quest Diagnostics Declares Quarterly Cash Dividend - PRNewsWire
- 5 weeks ago - What Does the Market Think About Quest Diagnostics? - Benzinga
- 5 weeks ago - Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types - PRNewsWire